{
  "symbol": "GLYC",
  "company_name": "Glycomimetics Inc",
  "ir_website": "http://www.glycomimetics.com/investors/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.glycomimetics.com/press-releases",
          "content": "  * [ Skip to content](#genesis-content)\n  * [ Skip to primary sidebar](#genesis-sidebar-primary)\n  * [ Skip to footer](#genesis-footer-widgets)\n\n\n\n  * 240.243.1201\n  * info@glycomimetics.com\n  * [](https://www.linkedin.com/company/819274)\n\n\n\n[](#)\n\n  * [Careers](https://glycomimetics.com/careers/)\n  * [Contact Us](https://glycomimetics.com/contact-us/)\n\n\n\n[ ![Glycomimetics](/sites/g/files/knoqqb82716/themes/site/nir_pid786/dist/images/gmi-logo-flush-2018_no_tagline.svg) ](https://glycomimetics.com \"Glycomimetics\")\n\n![](/sites/g/files/knoqqb82716/themes/site/nir_pid786/dist/images/subpages.png) ![](/sites/g/files/knoqqb82716/themes/site/nir_pid786/dist/images/header-overlay-1.png)\n\n#  Press Releases\n\n#  Press Releases \n\nYear None2024202320222021202020192018201720162015201420132012201120102009200820072005\n\n2024\n\nNovember 6, 2024 \n\n[GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting](/news-releases/news-release-details/glycomimetics-announces-new-uproleselan-clinical-data-will-be)\n\nOctober 29, 2024 \n\n[GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma](/news-releases/news-release-details/glycomimetics-enters-acquisition-agreement-crescent-biopharma)\n\nOctober 29, 2024 \n\n[GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint](/news-releases/news-release-details/glycomimetics-announces-national-cancer-institute-phase-23-study)\n\nJuly 25, 2024 \n\n[GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan](/news-releases/news-release-details/glycomimetics-announces-strategic-review-and-corporate)\n\nJune 4, 2024 \n\n[GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)](/news-releases/news-release-details/glycomimetics-announces-comprehensive-results-pivotal-phase-3)\n\nMay 29, 2024 \n\n[GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024](/news-releases/news-release-details/glycomimetics-host-key-opinion-leader-event-review-comprehensive)\n\nMay 6, 2024 \n\n[GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)](/news-releases/news-release-details/glycomimetics-announces-results-pivotal-phase-3-study)\n\nApril 25, 2024 \n\n[GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024](/news-releases/news-release-details/glycomimetics-report-first-quarter-2024-financial-results-may-9)\n\nMarch 27, 2024 \n\n[GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-fourth-3)\n\nMarch 13, 2024 \n\n[GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024](/news-releases/news-release-details/glycomimetics-report-fourth-quarter-and-2023-full-year-financial)\n\nDisplaying 1 - 10 of 13 \n\n## Footer\n\n### Questions?\n\nContact GlycoMimetics Today\n\n[Get in Touch](https://glycomimetics.com/contact-us/)\n\n©2024 GlycoMimetics All rights reserved. Website Design & Development: [Graphic Beans](https://graphicbeans.com/)\n\n[Site Map](https://glycomimetics.com/sitemap/) | [Terms of Use](https://glycomimetics.com/terms-of-use/) | [Privacy](https://glycomimetics.com/privacy-policy/) | [Contact Us](https://glycomimetics.com/contact-us/)\n"
        }
      ]
    },
    {
      "section_name": "Financials & Filings",
      "links": [
        {
          "title": "Annual Reports and Proxies",
          "url": "https://ir.glycomimetics.com/financial-information/annual-reports",
          "content": "  * [ Skip to content](#genesis-content)\n  * [ Skip to primary sidebar](#genesis-sidebar-primary)\n  * [ Skip to footer](#genesis-footer-widgets)\n\n\n\n  * 240.243.1201\n  * info@glycomimetics.com\n  * [](https://www.linkedin.com/company/819274)\n\n\n\n[](#)\n\n  * [Careers](https://glycomimetics.com/careers/)\n  * [Contact Us](https://glycomimetics.com/contact-us/)\n\n\n\n[ ![Glycomimetics](/sites/g/files/knoqqb82716/themes/site/nir_pid786/dist/images/gmi-logo-flush-2018_no_tagline.svg) ](https://glycomimetics.com \"Glycomimetics\")\n\n![](/sites/g/files/knoqqb82716/themes/site/nir_pid786/dist/images/subpages.png) ![](/sites/g/files/knoqqb82716/themes/site/nir_pid786/dist/images/header-overlay-1.png)\n\n# Annual Reports & Proxies\n\n#  Annual Reports & Proxies \n\n## Form 10-Ks\n\nFiled | View  \n---|---  \nApr 01, 2024 | [View HTML](/node/12136/html) [0001558370-24-004451.pdf](/static-files/c5b9d3da-dc05-46de-a362-71840e09f34e)  \nMar 27, 2024 | [View HTML](/node/12116/html) [0001558370-24-004013.pdf](/static-files/55bf74d7-f0af-40d2-9a90-2ad1d3e72279) [0001558370-24-004013.xls](/static-files/b14f7d4c-7d59-4fba-9c96-64c084317c35) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001558370-24-004013)  \nApr 21, 2023 | [View HTML](/node/11746/html) [0001558370-23-006405.pdf](/static-files/920f6d2e-47cf-4ccf-a4fc-5cda31c2624d)  \nMar 29, 2023 | [View HTML](/node/11711/html) [0001558370-23-004864.pdf](/static-files/9dfceeeb-89e5-4c0d-baf4-9f83f3192a8b) [0001558370-23-004864.xls](/static-files/8bf26f68-7031-4f1d-a479-81823a03fc73) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001558370-23-004864)  \n  \n## Proxy Statements\n\nFiled | View  \n---|---  \nNov 07, 2024 | [View HTML](/node/12401/html) [0001104659-24-115361.pdf](/static-files/79723031-508f-4acf-adde-848a2cadfbc8) [0001104659-24-115361.xls](/static-files/8f41bc6a-d33e-46a5-8cdf-f058921698f6)  \nOct 29, 2024 | [View HTML](/node/12366/html) [0001104659-24-112055.pdf](/static-files/a40f9732-d5ce-4020-81de-032ba7dfeb0a) [0001104659-24-112055.xls](/static-files/b33dd27d-4188-4d84-a38c-9e011e678ef9)  \nApr 01, 2024 | [View HTML](/node/12131/html) [0001558370-24-004448.pdf](/static-files/9daa3bb4-0256-40dc-8914-dd74f030f35d) [0001558370-24-004448.xls](/static-files/f998d71a-8c04-4bfd-86ba-9ddb3db86ec0)  \n  \n## Footer\n\n### Questions?\n\nContact GlycoMimetics Today\n\n[Get in Touch](https://glycomimetics.com/contact-us/)\n\n©2024 GlycoMimetics All rights reserved. Website Design & Development: [Graphic Beans](https://graphicbeans.com/)\n\n[Site Map](https://glycomimetics.com/sitemap/) | [Terms of Use](https://glycomimetics.com/terms-of-use/) | [Privacy](https://glycomimetics.com/privacy-policy/) | [Contact Us](https://glycomimetics.com/contact-us/)\n"
        },
        {
          "title": "Quarterly Results",
          "url": "https://ir.glycomimetics.com/financial-information/quarterly-results",
          "content": "  * [ Skip to content](#genesis-content)\n  * [ Skip to primary sidebar](#genesis-sidebar-primary)\n  * [ Skip to footer](#genesis-footer-widgets)\n\n\n\n  * 240.243.1201\n  * info@glycomimetics.com\n  * [](https://www.linkedin.com/company/819274)\n\n\n\n[](#)\n\n  * [Careers](https://glycomimetics.com/careers/)\n  * [Contact Us](https://glycomimetics.com/contact-us/)\n\n\n\n[ ![Glycomimetics](/sites/g/files/knoqqb82716/themes/site/nir_pid786/dist/images/gmi-logo-flush-2018_no_tagline.svg) ](https://glycomimetics.com \"Glycomimetics\")\n\n![](/sites/g/files/knoqqb82716/themes/site/nir_pid786/dist/images/subpages.png) ![](/sites/g/files/knoqqb82716/themes/site/nir_pid786/dist/images/header-overlay-1.png)\n\n#  Quarterly Results\n\n#  Quarterly Results \n\n[Show all](#)\n\n## 2024\n\nQ3\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-24-015537)\n\n\n\n\nQ2\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-24-011579)\n\n\n\n\nQ1\n\n  * [GlycoMimetics Corporate Update Call](/events/event-details/glycomimetics-first-quarter-2024-earnings-call)\n\n  * [GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)](/news-releases/news-release-details/glycomimetics-announces-results-pivotal-phase-3-study)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-24-007632)\n\n\n\n\n## 2023\n\nQ4\n\n  * [GlycoMimetics Fourth Quarter and Year-End 2023 Earnings Call](/events/event-details/glycomimetics-fourth-quarter-and-year-end-2023-earnings-call)\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-fourth-3)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001558370-24-004013)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Third Quarter 2023 Earnings Call](/events/event-details/glycomimetics-third-quarter-2023-earnings-call)\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-third-2)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-23-017505)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Second Quarter 2023 Earnings Call](/events/event-details/glycomimetics-second-quarter-2023-earnings-call)\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-second-2)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-23-012814)\n\n\n\n\nQ1\n\n  * [GlycoMimetics 1st Quarter 2023 Earnings Call](/events/event-details/glycomimetics-1st-quarter-2023-earnings-call)\n\n  * [GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-first-1)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-23-007744)\n\n\n\n\n## 2022\n\nQ4\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-fourth-2)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001558370-23-004864)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-third-1)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-22-017036)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-second-1)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-22-011770)\n\n\n\n\nQ1\n\n  * [GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-first-0)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-22-006260)\n\n\n\n\n## 2021\n\nQ4\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-fourth-1)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001558370-22-002737)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-third-0)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-21-014003)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2021](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-second-0)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-21-010410)\n\n\n\n\nQ1\n\n  * [GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-first)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-21-005473)\n\n\n\n\n## 2020\n\nQ4\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-fourth-0)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001558370-21-002222)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-third)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-20-013021)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-second)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-20-008841)\n\n\n\n\nQ1\n\n  * [GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020](/news-releases/news-release-details/glycomimetics-reports-operational-highlights-and-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-20-004879)\n\n\n\n\n## 2019\n\nQ4\n\n  * [GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2019](/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-fourth)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001558370-20-001723)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments](/news-releases/news-release-details/glycomimetics-reports-third-quarter-2019-financial-results-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-19-010290)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Reports Second Quarter 2019 Financial Results and Recent Operational Highlights](/news-releases/news-release-details/glycomimetics-reports-second-quarter-2019-financial-results-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-19-006741)\n\n\n\n\nQ1\n\n  * [GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights](/news-releases/news-release-details/glycomimetics-reports-first-quarter-2019-results-and-recent)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-19-003803)\n\n\n\n\n## 2018\n\nQ4\n\n  * [GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results](/news-releases/news-release-details/glycomimetics-reports-fourth-quarter-and-year-end-2018-results)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001558370-19-001537)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements](/news-releases/news-release-details/glycomimetics-reports-third-quarter-2018-results-and-highlights)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-18-008314)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements](/news-releases/news-release-details/glycomimetics-reports-second-quarter-2018-results-and-highlights)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-18-006888)\n\n\n\n\nQ1\n\n  * [GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018](/news-releases/news-release-details/glycomimetics-report-first-quarter-2018-financial-results-may-3)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001558370-18-003836)\n\n\n\n\n## 2017\n\nQ4\n\n  * [GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results](/news-releases/news-release-details/glycomimetics-reports-fourth-quarter-and-year-end-2017-results)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001558370-18-001553)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Reports Program Updates and Third Quarter 2017 Results](/news-releases/news-release-details/glycomimetics-reports-program-updates-and-third-quarter-2017)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Reports Program Updates and Second Quarter 2017 Results](/news-releases/news-release-details/glycomimetics-reports-program-updates-and-second-quarter-2017)\n\n\n\n\nQ1\n\n  * [GlycoMimetics Reports Program Updates and First Quarter 2017 Results](/news-releases/news-release-details/glycomimetics-reports-program-updates-and-first-quarter-2017)\n\n\n\n\n## 2016\n\nQ4\n\n  * [GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results](/news-releases/news-release-details/glycomimetics-reports-fourth-quarter-and-year-end-2016-results)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development](/news-releases/news-release-details/glycomimetics-reports-third-quarter-2016-results-and-progress)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Reports Second Quarter 2016 Results](/news-releases/news-release-details/glycomimetics-reports-second-quarter-2016-results)\n\n\n\n\nQ1\n\n  * [GlycoMimetics Reports First Quarter 2016 Results](/news-releases/news-release-details/glycomimetics-reports-first-quarter-2016-results)\n\n\n\n\n## 2015\n\nQ4\n\n  * [GlycoMimetics Reports Fourth Quarter and Year-End 2015 Results](/news-releases/news-release-details/glycomimetics-reports-fourth-quarter-and-year-end-2015-results)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Reports Third Quarter 2015 Results](/news-releases/news-release-details/glycomimetics-reports-third-quarter-2015-results)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Reports Second Quarter 2015 Results](/news-releases/news-release-details/glycomimetics-reports-second-quarter-2015-results)\n\n\n\n\nQ1\n\n  * [GlycoMimetics Reports First Quarter 2015 Results](/news-releases/news-release-details/glycomimetics-reports-first-quarter-2015-results)\n\n\n\n\n## 2014\n\nQ4\n\n  * [GlycoMimetics Reports Fourth Quarter and Year-End 2014 Results](/news-releases/news-release-details/glycomimetics-reports-fourth-quarter-and-year-end-2014-results)\n\n\n\n\nQ3\n\n  * [GlycoMimetics Reports Third Quarter 2014 Results](/news-releases/news-release-details/glycomimetics-reports-third-quarter-2014-results)\n\n\n\n\nQ2\n\n  * [GlycoMimetics Reports Second Quarter 2014 Results](/news-releases/news-release-details/glycomimetics-reports-second-quarter-2014-results)\n\n\n\n\nQ1\n\n  * [GlycoMimetics Reports First Quarter 2014 Results](/news-releases/news-release-details/glycomimetics-reports-first-quarter-2014-results)\n\n\n\n\n## Footer\n\n### Questions?\n\nContact GlycoMimetics Today\n\n[Get in Touch](https://glycomimetics.com/contact-us/)\n\n©2024 GlycoMimetics All rights reserved. Website Design & Development: [Graphic Beans](https://graphicbeans.com/)\n\n[Site Map](https://glycomimetics.com/sitemap/) | [Terms of Use](https://glycomimetics.com/terms-of-use/) | [Privacy](https://glycomimetics.com/privacy-policy/) | [Contact Us](https://glycomimetics.com/contact-us/)\n"
        }
      ]
    }
  ]
}